Novo's Oral Wegovy Sparks Catalyst Debate Amid Persistent Share Losses

What happened

Novo Nordisk, once the clear leader in GLP-1 weight-loss therapies, has watched Eli Lilly overtake it in injectables and now also challenge its oral franchise. The company's oral Wegovy has shown strong early prescription uptake, exceeding 265,000 weekly scripts by mid-July, but revenue conversion is being pressured by aggressive rebating and payer dynamics. A new article from The Motley Fool questions whether Novo has finally found a catalyst to reverse the narrative, pointing to its first-mover status in pills. However, the underlying fundamentals remain mixed: Novo lost volume share in both obesity and diabetes during 2025 and guides for flat-to-declining adjusted operating profit in 2026. Thus, the potential catalyst is still unproven, requiring evidence that oral volume translates into stabilized revenue and margins.

Implication

Near-term, Novo's valuation at 11.6x earnings already prices in substantial competitive damage, limiting downside but also capping upside without clear execution beats. The key monitorable over the next 6-9 months is whether oral Wegovy can sustain high script growth while net prices stabilize, especially as Lilly's Foundayo gains PBM access and Medicare price resets loom in 2027. Failure to show improved adjusted operating profit growth or regained GLP-1 share would likely trigger further multiple compression, pushing the stock toward the bear case of $38. Conversely, if oral Wegovy scales internationally and injectable mix stabilizes, shares could re-rate toward $60 as the bull scenario suggests. Given the current balance of evidence, adding on weakness below $42 appears more prudent than chasing momentum until the thesis is confirmed.

Thesis delta

No material change to the existing wait thesis; the article highlights the same tension between first-mover advantage in oral GLP-1 and ongoing competitive losses. Oral Wegovy adoption is real, but it has not yet proven it can offset pricing pressure and lost injectable share to justify a more bullish stance. The investment case remains hinged on upcoming proof points around revenue quality and market share trends.